The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load

AIDS ◽  
2000 ◽  
Vol 14 (14) ◽  
pp. 2129-2136 ◽  
Author(s):  
Veronica Miller ◽  
Caroline A. Sabin ◽  
Andrew N. Phillips ◽  
Carsten Rottmann ◽  
Holger Rabenau ◽  
...  
2006 ◽  
Vol 17 (3) ◽  
pp. 205-207 ◽  
Author(s):  
Simon Rackstraw ◽  
Jeanette Meadway ◽  
James Bingham ◽  
Safa Al-Sarraj ◽  
Ian Everall

We report an individual who had HIV-associated dementia, but a good clinical response to antiretroviral therapy, with a rising CD4 count and undetectable viral load. A severe leukoencephalopathy was noted at postmortem; however, no HIV immunopositive cells were found in the brain, suggesting that this new severe leukoencephalopathy is associated with immune reconstitution.


2016 ◽  
Vol 10 (07) ◽  
pp. 762-769
Author(s):  
Luciana Brosina De Leon ◽  
Cristiane Valle Tovo ◽  
Dimas Alexandre Kliemann ◽  
Angelo Alves De Mattos ◽  
Alberi Adolfo Feltrin ◽  
...  

Introduction: Many patients coinfected with the human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are using highly active antiretroviral therapy (HAART) and HCV therapy with peginterferon (PEG-IFN) and ribavirina (RBV) because the use of direct-acting antivirals is not a reality in some countries. To know the impact of such medications in the sustained virological response (SVR) during HCV treatment is of great importance. Methodology: This was a retrospective cohort study of 215 coinfected HIV/HCV patients. The patients were treated with PEG-IFN and RBV between 2007 and 2013 and analyzed by intention to treat. Treatment-experienced patients to HCV and carriers of hepatitis B were excluded. Demographic data (gender, age), mode of infection, HCV genotype, HCV viral load, hepatic fibrosis, HIV status, and type of PEG were evaluated. One hundred eighty-eight (87.4%) patients were using HAART. Results: SVR was achieved in 55 (29.3%) patients using HAART and in 9 (33.3%) patients not using HAART (p = 0.86). There was no difference in SVR between different HAART medications and regimens using two reverse transcriptase inhibitor nucleosides (NRTIs) or the use of protease inhibitors and non-NRTIs (27.1% versus 31.5%; p = 0.61). The predictive factors for obtaining SVR were low HCV viral load, non-1 genotype, and the use of peginterferon-α2a. Conclusions: The use of HAART does not influence the SVR of HCV under PEG-IFN and RBV therapy in HIV/HCV coinfected patients.


AIDS ◽  
2005 ◽  
Vol 19 (16) ◽  
pp. 1843-1847 ◽  
Author(s):  
Lucia Palmisano ◽  
Marina Giuliano ◽  
Emanuele Nicastri ◽  
Maria Franca Pirillo ◽  
Mauro Andreotti ◽  
...  

AIDS ◽  
2001 ◽  
Vol 15 (6) ◽  
pp. 665-673 ◽  
Author(s):  
Nicole Ngo-Giang-Huong ◽  
Christiane Deveau ◽  
Isabelle Da Silva ◽  
Isabelle Pellegrin ◽  
Alain Venet ◽  
...  

2020 ◽  
Vol 2020 ◽  
pp. 1-7 ◽  
Author(s):  
Sylvester Yao Lokpo ◽  
Patrick Jnr Ofori-Attah ◽  
Louis Selassie Ameke ◽  
Christian Obirikorang ◽  
Verner Ndudiri Orish ◽  
...  

Background. The WHO targets to end HIV/AIDS as a public health problem by 2030. The introduction of the ambitious “90-90-90” strategy to attain this target is expected to be achieved by the year 2020. However, there is lack of regional data, especially on the third “90.” This study sought to assess the rate and associated factors of viral suppression among people living with HIV (PLWH) on highly active antiretroviral therapy (HAART) at the Antiretroviral Therapy (ART) Clinic in a Ghanaian health facility. Method. The study design was a retrospective analysis of secondary data of 284 HIV registrants on HAART for at least 6 months at the ART Clinic from July 2016 to April 2019. Data on sociodemography including age, gender, marital status, education, and occupation as well as pharmacological (type of medication and duration on medication) and laboratory variable (current viral load results) were extracted from patients’ folders. Viral suppression and failure were determined using the WHO definitions (viral suppression as viral load <1000 copies/ml and virologic failure ≥1000 copies/ml). Regular clinic attendance (used as a proxy measure for medication adherence) was defined as consistent monthly clinic attendance for HAART medication and other clinical management within the past 12 months. Results. Out of the 284 HIV patients, 195 (69%) achieved viral suppression. Of the 195 who were virally suppressed, 77 (39.5%) had undetectable levels, with a similar proportion (39.5%) achieving viral load results ranging from 20 to 200 copies/ml. Moreover, 27 (13.8%) patients had viral load ranging from 201 to 500 copies/ml while 14 (7.2%) recorded viral load from 501 to 1000 copies/ml. No clear pattern in the viral suppression rate was associated with the age groups (p=0.1152). However, regular clinic attendance (used as proxy for medication adherence) (p<0.0001) and being on HAART for more than three (3) years (p=0.03) were associated with viral suppression. Conclusion. The rate of viral suppression among PLWH on HAART in the Ho municipality fell short of the WHO target. However, the study identified regular ART clinic attendance and treatment >3 years as factors associated with viral suppression.


2007 ◽  
Vol 36 (3) ◽  
pp. 136-141 ◽  
Author(s):  
K. M. R. Umadevi ◽  
K. Ranganathan ◽  
S. Pavithra ◽  
R. Hemalatha ◽  
T. R. Saraswathi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document